Clinical Trial Update: Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial investigating durvalumab, tremelimumab, and hypofractionated radiation therapy in patients with recurrent or metastatic head and neck squamous ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: University of Washington | Conditions: Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-06-12